

## Literatura ACTA MEDICINAE Speciál 2017

- 2 **Editorial**  
prof. MUDr. Tomáš Papajík, CSc. Přednosta Hemato-onkologické kliniky FNOL a LF UP v Olomouci
- 2 **Můj boxer, můj společník v nemoci**  
MUDr. Renata Urbanová, Ph.D. Hemato-onkologická klinika FN OL a LF UP, Olomouc
- 2 **Štvrtročné prerušenie liečby ibrutinibom pri CLL pre závažné infekcie**  
MUDr. Alexander Wild Hematologické oddelenie FNŠP F. D. Roosevelta v Banskej Bystrici
- 2 **Ibrutinib v léčbě opakovaně relabující nemocné s chronickou lymfocytární leukemií / lymfomem z malých lymfocytů s nepříznivými genetickými změnami a postižením skeletu**  
MUDr. Pavlína Ryznerová Hemato-onkologická klinika, Klinika nukleární medicíny FN Olomouc a LF UP, Olomouc
- 2 **Antikoagulanciá u pacienta s cieľnou liečbou ibrutinibom**  
MUDr. Ľubica Váľková, Ph.D. Klinika hematológie a transfuziológie, JLF UK a Univerzitná Nemocnica Martin
- 3 **Úspěšná léčba ibrutinibem u pacientky s chronickou lymfocytární leukemií a nutností antiagregační terapie**  
MUDr. Jakub Trizuljak Interní hematologická a onkologická klinika LF MU, CEITEC MU a FN Brno
- 3 **Recidivujúce respiračné infekcie u pacienta s refraktérnou chronickou lymfocytovou leukémiou (CLL) liečeného ibrutinibom**  
MUDr. Ľudmila Demitrovičová, Ph.D. Oddelenie onkohematológie II., Národný onkologický ústav, Bratislava
- 3 **Efekt léčby ibrutinibem u relapsu CLL po alogenní transplantaci krvetvorných buněk**  
MUDr. Veronika Váľková, CSc.  
Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha
- 3 **Skúsenosti s novou liečbou u pacienta s lymfómom z plášťových buniek**  
MUDr. Juraj Chudej, Ph.D. Klinika hematológie a transfuziológie Jesseniovej lekárskej fakulty v Martine, Univerzity Komenského v Bratislave, Univerzitná nemocnica v Martine
- 4 **Úspěšná léčba ibrutinibem i přes infekční komplikace a hlubokou neutropenii**  
MUDr. Jakub Trizuljak Interní hematologická a onkologická klinika LF MU, CEITEC MU a FN Brno
- 4 **Ibrutinib jako přemostění k alogenní transplantaci kostní dřeně**  
doc. MUDr. Pavel Klener, Ph.D. I. Interní klinika – klinika hematologie VFN, Praha

## Editorial

prof. MUDr. Tomáš Papajík, CSc. Přednosta Hemato-onkologické kliniky FNOL a LF UP v Olomouci

- 1 Byrd, J. C. – Furman, R. R. – Coutre, S. E., et al.: Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*, 2015, 125, s. 2497–2506.
- 2 Wang, M. L. – Rule, S. – Martin, P., et al.: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*, 2013, 369, s. 507–516.
- 3 Treon, S. P. – Tripsas, C. K. – Meid, K., et al.: Ibrutinib in previously treated Waldenström's macroglobulinemia. *N Engl J Med*, 2015, 372, s. 1430–1440.
- 4 Burger, J. A. – Keating, M. J. – Wierda, W. G., et al.: Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. *Lancet Oncol*, 2014, 15, s. 1090–1099.
- 5 Chanan-Khan, A. – Cramer, P. – Demirkan, F., et al.: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. *Lancet Oncol*, 2016, 17, s. 200–211.
- 6 Burger, J. A. – Tedeschi, A. – Barr, P. M., et al.: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med*, 2015, 373, s. 2425–2437.

## Můj boxer, můj společník v nemoci

MUDr. Renata Urbanová, Ph.D. Hemato-onkologická klinika FN OL a LF UP, Olomouc

- 1 Dreger, P. – Schetelig, J. – Andersen, N., et al.: Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? *Blood*, 2014, 124, s. 3841–3849.

## Štvrťročné prerušenie liečby ibrutinibom pri CLL pre závažné infekcie

MUDr. Alexander Wild Hematologické oddelenie FNŠP F. D. Roosevelta v Banskej Bystrici

- 1 Byrd, J. C. – Furman, R. R. – Coutre, S. E., et al.: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2013, 369, s. 32–42.
- 2 Arthurs, B. – Winderle, K. – Hsu, M., et al.: Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. *Respiratory Medicine Case Reports*, 2017, 21, s. 27–29.
- 3 Lionakis, M. S. – Dunleavy, K. – Roschewski, M., et al.: Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. *Cancer Cell*, 2017, 31, s. 833–845.e5.
- 4 UK CLL forum: Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. *Haematologica*, 2016, 101, s. 1563–1572.
- 5 Barr, P. M. – Brown, J. E. R. – Hilmen, P., et al.: Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. *Blood*, 2017, 129, s. 2612–2615.

## Ibrutinib v léčbě opakovaně relabující nemocné s chronickou lymfocytární leukémií / lymfomem z malých lymfocytů s nepříznivými genetickými změnami a postižením skeletu

MUDr. Pavlína Ryznerová

Hemato-onkologická klinika, Klinika nukleární medicíny FN Olomouc a LF UP, Olomouc

- 1 Varma, G. – Johnson, T. P. – Advani, R. H.: Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. *Clin Adv Hematol Oncol*, 2016, 14, s. 543–554.
- 2 Brown, J. R. – Hallek, M. J. – Pagel, J. M.: Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination? *Am Soc Clin Oncol Educ Book*, 2016, 35, s. e387–e398.
- 3 Thompson, P. A. – O'Brien, S. M. – Xiao, L., et al.:  $\beta_2$ -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. *Cancer*, 2016, 122, s. 565–573.

## Antikoagulanciá u pacienta s cielenou liečbou ibrutinibom

MUDr. Ľubica Váleková, Ph.D. Klinika hematológie a transfuziológie, JLF UK a Univerzitná Nemocnica Martin

- 1 Demitrovičová, L. – Mikušková, E.: Patogenéza chronickej lymfocytovej leukémie. *Onkológia (Bratislava)*, 2014, 9, s. 94–99.
- 2 Copáková, L. – Piačková, B. – Leitnerová, M.: Význam delécie a mutácie génu TP53 a ďalších prognostických markerov u pacientov s CLL. *Onkológia (Bratislava)*, 2014, 9, s. 100–103.
- 3 Štecová, N.: Liečba relapsu a refraktérnej chronickej lymfocytovej leukémie. *Onkológia (Bratislava)*, 2014, 9, s. 301–304.
- 4 Obrtlíková, P.: Moderní individualizovaná liečba chronickej lymfocytárnej leukémie. *Onkologie*, 2013, 7, s. 24–28.
- 5 SPC lieku Imbruvica, revízia textu 02/2015.
- 6 Zenz, T. – Eichhorst, B. – Busch, R., et al.: TP53 mutácie a prežitie v chronickej lymfocytárnej leukémii. *J Clin Oncol*, 2010, 28, s. 4473–4479.
- 7 Burger, J. A. – Tedeschi, A. – Barret, P. M., et al.: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med*, 2015, 373, s. 2425–2437.
- 8 Lysák, D. – Schwarz, J.: Liečba chronickej lymfocytárnej leukémie s abeťáci TP53. *Klin Onkol*, 2015, 28, suppl. 3, s. 3539–3544.

# Úspěšná léčba ibrutinibem u pacientky s chronickou lymfocytární leukémií a nutností antiagregační terapie

MUDr. Jakub Trizuljak Interní hematologická a onkologická klinika LF MU, CEITEC MU a FN Brno

- 1 Byrd, J. C. – Brown, J. R. – O'Brien, S., et al.: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*, 2014, 371, s. 213–223.
- 2 Wang, M. L. – Rule, S. – Martin, P., et al.: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*, 2013, 369, s. 507–516.
- 3 Liu, J. – Fitzgerald, M. E. – Berndt, M. C., et al.: Bruton tyrosine kinase is essential for botrocetin/WWF-induced signaling and GPIIb-dependent thrombus formation in vivo. *Blood*, 2006, 108, s. 2596–2603.
- 4 Farooqui, M.: Ibrutinib rapidly improves platelet counts in CLL/SLL patients and has minimal effects on platelet aggregation. *ASH*, 2012, abstrakt 1789.
- 5 Lipsky, A. H. – Farooqui, M. Z. – Tian, X., et al.: Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. *Haematologica*, 2015, 100, s. 1571–1578.

## Recidivující respirační infekcie u pacienta s refraktérnou chronickou lymfocytovou leukémiou (CLL) liečeného ibrutinibom

MUDr. Ľudmila Demitrovičová, Ph.D. Oddelenie onkohematológie II., Národný onkologický ústav, Bratislava

- 1 SPC prípravku Imbruvica 140 mg capsules, 30. 8. 2017.
- 2 Byrd, J. C. – Coutre, S. E.: Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*, 2015, 125, s. 497–2506.
- 3 Dubovsky, J. A. – Beckwith, K. A. – Natarajan, G.: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood*, 2013, 122, s. 2539–2549.
- 4 Sun, C. – Tian, X. – Lee, S.: Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. *Blood*, 2015, 126, s. 2213–2219.
- 5 Demitrovičová, L. – Mikusková, E. – Oravcová, I., et al.: Infectious complications in chronic lymphocytic leukemia – a retrospective analysis: single institution experience. *Neoplasma*, 2017, 64, s. 478–481.

## Efekt léčby ibrutinibem u relapsu CLL po alogenní transplantaci krvetvorných buněk

MUDr. Veronika Válková, CSc.

Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha

- 1 Dreger, P. – Corradini, P. – Kimby, E., et al.: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. *Leukemia*, 2007, 21, s. 12–17.
- 2 Dreger, P. – Schetelig, J. – Andersen, N., et al.: Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? *Blood*, 2014, 124, s. 3841–3849.
- 3 Herth, I. – Dietrich, S. – Benner, A., et al.: The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. *Ann Oncol*, 2014, 25, s. 200–206.
- 4 Dreger, P. – Schnaider, A. – Zenz, T., et al.: TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. *Blood*, 2013, 121, s. 3284–3288.
- 5 Montserrat, E. – Dreger, P.: Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation. *J Clin Oncol*, 2015, 33, s. 1527–1529.
- 6 Rozovski, U. – Benjamini, O. – Jain, P., et al.: Outcomes of patients with chronic lymphocytic leukemia and Richter's transformation after transplantation failure. *J Clin Oncol*, 2015, 33, s. 1557–1563.
- 7 Link, C. S. – Teipel, R. – Heidenreich, F., et al.: Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. *Bone Marrow Transplant*, 2016, 51, s. 793–798.
- 8 Dubovsky, J. A. – Beckwith, K. A. – Natarajan, G., et al.: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood*, 2013, 122, s. 2539–2550.
- 9 Dubovsky, J. – Flynn, R. – Du, J., et al.: Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. *J Clin Invest*, 2014, 124, s. 4867–4876.
- 10 Schutt, S. D. – Fu, J. – Nguyen, H., et al.: Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice. *PLoS ONE*, 2015, 10, s. e0137641.

## Skúsenosti s novou liečbou u pacienta s lymfómom z plášťových buniek

MUDr. Juraj Chudej, Ph.D. Klinika hematológie a transfuziológie Jesseniovej lekárskej fakulty v Martine, Univerzity Komenského v Bratislave, Univerzitná nemocnica v Martine

- 1 Geisler, C. – Kolstad, A. – Laurell, A., et al.: Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAM + autologous stem-cell support: still very long survival but late relapses do occur. *Br J Haematol*, 2012, 158, s. 355–362.
- 2 Romaguera, J. – Fayad, L. – Feng, L., et al.: Ten-year follow-up after intense chemoimmunotherapy with Rituximab-Hyper CVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. *Br J Haematol*, 2010, 150, s. 200–208.
- 3 Merli, F. – Luminari, S. – Ilariucci, F., et al.: Rituximab plus Hyper CVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. *Br J Haematol*, 2012, 156, s. 346–353.
- 4 Zhou, Y. – Wang, H. – Fang, W., et al.: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. *Cancer*, 2008, 113, s. 791–798.
- 5 Rummel, M. – Niederle, N. – Maschmeyer, G., et al.: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*, 2013, 381, s. 1203–1210.
- 6 Flinn, I. – van der Jagt, R. – Kahl, B., et al.: Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. *Blood*, 2014, 123, s. 2944–2952.
- 7 Ballová, V.: Liečba indolentných B-bunkových lymfómov. *Onkológia*, 2014, 9, s. 80–84.
- 8 Wang, M. L. – Blum, K. A. – Martin, P., et al.: Long-term follow-up of CML patients treated with single-agent ibrutinib: up dated safety and efficacy results. *Blood*, 2015, 126, s. 739–745.

# Úspěšná léčba ibrutinibem i přes infekční komplikace a hlubokou neutropenii

MUDr. Jakub Trizuljak Interní hematologická a onkologická klinika LF MU, CEITEC MU a FN Brno

- 1 Byrd, J. C. – Brown, J. R. – O'Brien, S., et al.: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*, 2014, 371, s. 213–223.
- 2 Burger, J. A. – Tedeschi, A. – Barr, P. M., et al.: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med*, 2015, 373, s. 2425–2437.

## Ibrutinib jako přemostění k alogenní transplantaci kostní dřeně

doc. MUDr. Pavel Klener, Ph.D. I. Interní klinika – klinika hematologie VFN, Praha

- 1 Cheah, C. Y. – Seymour, J. F. – Wang, M. L., et al.: Mantle cell lymphoma. *J Clin Oncol*, 2016, 34, s. 1256–1269.
- 2 Dreyling, M. – Ferrero, S.: The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? *Haematologica*, 2016, 101, s. 104–114.
- 3 Tessoulin, B. – Ceballos, P. – Chevallier, P., et al.: Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. *Bone Marrow Transplantation*, 25. 4. 2016, doi: 10.1038/bmt.2016.
- 4 Vaughn, J. E. – Sorror, M. L. – Storer, B. E., et al.: Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. *Cancer*, 2015, 121, s. 3709–3716.
- 5 Lee, H. J. – Gallardo, M. – Ma, H., et al.: p53-independent ibrutinib responses in an Emu-TCL1 mouse model demonstrates efficacy in high-risk CLL. *Blood Cancer J*, 2016, 6, s. e434.
- 6 Wang, M. L. – Rule, S. – Martin, P., et al.: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *New Eng J Med*, 2013, 369, s. 507–516.
- 7 Dreyling, M. – Jurczak, W. – Jerkeman, M., et al.: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. *Lancet*, 2016, 387, s. 770–778.
- 8 Tucker, D. L. – Naylor, G. – Krueger, A., et al.: Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement – a multi-centre case series from the United Kingdom. *Br J Haematol*, 2017, 178, s. 327–329, doi: 10.1111/bjh.14122, Epub 16. 5. 2016.
- 9 Martin, P. – Maddocks, K. – Leonard, J. P., et al.: Postibrutinib outcomes in patients with mantle cell lymphoma. *Blood*, 2016, 127, s. 1559–1563.
- 10 Cheah, C. Y. – Chihara, D. – Romaguera, J. E., et al.: Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. *An Oncol*, 2015, 26, s. 1175–1179.
- 11 Sorror, M. – Storer, B. – Sandmaier, B. M., et al.: Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. *Cancer*, 2008, 112, s. 1992–2001.
- 12 Sorror, M. L. – Maris, M. B. – Storb, R., et al.: Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood*, 2005, 106, s. 2912–2919.